Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.
Brian Andrew Van TineMatthew A InghamSteven AttiaChristian F MeyerJohn D BairdEsther Brooks-AsplundDhiren D'SilvaRonald KongAnthony MwathaKylie O'KeefeMarla WeetallRobert SpiegelGary K SchwartzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.